This project will characterize how advance age alters phenytoin and carbamazepine pharmacokinetics and metabolism. Specifically, this project will determine if the cytochrome P-450 isoenzymes (CYP2C9, CYP2C18, CYP2C19, and CYP3A4) responsible for metabolism of these drugs decline in the elderly. Complete characterization of antiepileptic drug (AED) pharmacokinetics and metabolism requires intravenous drug administration and intensive blood and urine sampling under steady-state conditions. This project will use an approach new to disposition studies in elderly patients: stable-labelled isotopes and chromatographic/mass spectrophotometry. Sixty elderly (greater than or equal to 65 years) men and women distributed among three age groups (young-old, old, and old-old) taking phenytoin will be recruited from participating clinics and nursing homes. The results from the sixty elderly will be compared to the results obtained from ten younger patients. The same approach will be used for carbamazepine. A small dose of stable phenytoin or carbamazepine labelled isotope will be administered intravenously and blood and urine samples will be collected over five days. Both total and unbound plasma drug and metabolite concentrations and urine drug and metabolite concentrations will be measured. Absolute bioavailability, free fraction, distribution volume, elimination half-life, and clearance will be calculated as will the contributions of CYP2C9, CYP2C18, CYP2C19, and CYP3A4 metabolic pathways to phenytoin or carbamazepine elimination. These results will be used to determine if the mechanism (s) for pharmacokinetic changes in the elderly are due to alterations in absorption, protein binding, or enzyme activity. Pharmacokinetic parameters obtained in elderly patients will be compared to those from younger patients. In addition, pharmacokinetic changes among the three elderly groups will be assessed by multivariant, regression analysis. Our results will be used to develop rational guidelines for dosage, dosing frequency, and monitoring of total and free drug levels.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016308-19
Application #
6205006
Study Section
Project Start
1999-06-01
Project End
2000-05-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
19
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Conway, Jeannine M; Eberly, Lynn E; Collins, Joseph F et al. (2017) Factors in Variability of Serial Gabapentin Concentrations in Elderly Patients with Epilepsy. Pharmacotherapy 37:1197-1203
Polepally, Akshanth R; Remmel, Rory P; Brundage, Richard C et al. (2015) Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. J Clin Pharmacol 55:1101-8
Patel, Sima I; Birnbaum, Angela K; Cloyd, James C et al. (2015) Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy. CNS Drugs 29:1009-22
Conway, Jeannine M; Birnbaum, Angela K; Leppik, Ilo E et al. (2014) Safety of an intravenous formulation of lamotrigine. Seizure 23:390-2
Ghodke-Puranik, Yogita; Thorn, Caroline F; Lamba, Jatinder K et al. (2013) Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 23:236-41
Ahmed, Ghada F; Brundage, Richard C; Marino, Susan E et al. (2013) Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy. J Clin Pharmacol 53:276-84
Puranik, Yogita Ghodke; Birnbaum, Angela K; Marino, Susan E et al. (2013) Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 14:35-45
Punyawudho, Baralee; Ramsay, Eugene R; Brundage, Richard C et al. (2012) Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit 34:176-81
Marino, S E; Birnbaum, A K; Leppik, I E et al. (2012) Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther 91:483-8
Leppik, Ilo E; Walczak, Thaddeus S; Birnbaum, Angela K (2012) Challenges of epilepsy in elderly people. Lancet 380:1128-30

Showing the most recent 10 out of 96 publications